Meghan Mooring1, Brendan H Fowl2, Shelly Z C Lum2, Ye Liu1, Kangning Yao1, Samir Softic2,3, Rory Kirchner4, Aaron Bernstein5, Aatur D Singhi6, Daniel G Jay5, C Ronald Kahn3, Fernando D Camargo7,8, Dean Yimlamai1,2,6. 1. Division of Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 2. Division of Gastroenterology and Nutrition, Department of Pediatrics, Boston Children's Hospital, Boston, MA. 3. Section on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA. 4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA. 5. Department of Developmental, Molecular, and Chemical Biology, School of Medicine, Tufts University, Boston, MA. 6. Pittsburgh Liver Research Center, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA. 7. The Stem Cell Program, Boston Children's Hospital, Boston, MA. 8. Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA.
Abstract
BACKGROUND AND AIMS: Activated hepatocytes are hypothesized to be a major source of signals that drive cirrhosis, but the biochemical pathways that convert hepatocytes into such a state are unclear. We examined the role of the Hippo pathway transcriptional coactivators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in hepatocytes to facilitate cell-cell interactions that stimulate liver inflammation and fibrosis. APPROACH AND RESULTS: Using a variety of genetic, metabolic, and liver injury models in mice, we manipulated Hippo signaling in hepatocytes and examined its effects in nonparenchymal cells to promote liver inflammation and fibrosis. YAP-expressing hepatocytes rapidly and potently activate the expression of proteins that promote fibrosis (collagen type I alpha 1 chain, tissue inhibitor of metalloproteinase 1, platelet-derived growth factor c, transforming growth factor β2) and inflammation (tumor necrosis factor, interleukin 1β). They stimulate expansion of myofibroblasts and immune cells, followed by aggressive liver fibrosis. In contrast, hepatocyte-specific YAP and YAP/TAZ knockouts exhibit limited myofibroblast expansion, less inflammation, and decreased fibrosis after CCl4 injury despite a similar degree of necrosis as controls. We identified cellular communication network factor 1 (CYR61) as a chemokine that is up-regulated by hepatocytes during liver injury but is expressed at significantly lower levels in mice with hepatocyte-specific deletion of YAP or TAZ. Gain-of-function and loss-of-function experiments with CYR61 in vivo point to it being a key chemokine controlling liver fibrosis and inflammation in the context of YAP/TAZ. There is a direct correlation between levels of YAP/TAZ and CYR61 in liver tissues of patients with high-grade nonalcoholic steatohepatitis. CONCLUSIONS: Liver injury in mice and humans increases levels of YAP/TAZ/CYR61 in hepatocytes, thus attracting macrophages to the liver to promote inflammation and fibrosis.
BACKGROUND AND AIMS: Activated hepatocytes are hypothesized to be a major source of signals that drive cirrhosis, but the biochemical pathways that convert hepatocytes into such a state are unclear. We examined the role of the Hippo pathway transcriptional coactivators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in hepatocytes to facilitate cell-cell interactions that stimulate liver inflammation and fibrosis. APPROACH AND RESULTS: Using a variety of genetic, metabolic, and liver injury models in mice, we manipulated Hippo signaling in hepatocytes and examined its effects in nonparenchymal cells to promote liver inflammation and fibrosis. YAP-expressing hepatocytes rapidly and potently activate the expression of proteins that promote fibrosis (collagen type I alpha 1 chain, tissue inhibitor of metalloproteinase 1, platelet-derived growth factor c, transforming growth factor β2) and inflammation (tumornecrosis factor, interleukin 1β). They stimulate expansion of myofibroblasts and immune cells, followed by aggressive liver fibrosis. In contrast, hepatocyte-specific YAP and YAP/TAZ knockouts exhibit limited myofibroblast expansion, less inflammation, and decreased fibrosis after CCl4injury despite a similar degree of necrosis as controls. We identified cellular communication network factor 1 (CYR61) as a chemokine that is up-regulated by hepatocytes during liver injury but is expressed at significantly lower levels in mice with hepatocyte-specific deletion of YAP or TAZ. Gain-of-function and loss-of-function experiments with CYR61 in vivo point to it being a key chemokine controlling liver fibrosis and inflammation in the context of YAP/TAZ. There is a direct correlation between levels of YAP/TAZ and CYR61 in liver tissues of patients with high-grade nonalcoholic steatohepatitis. CONCLUSIONS:Liver injury in mice and humans increases levels of YAP/TAZ/CYR61 in hepatocytes, thus attracting macrophages to the liver to promote inflammation and fibrosis.
Authors: Kilangsungla Yanger; Yiwei Zong; Lara R Maggs; Suzanne N Shapira; Ravi Maddipati; Nicole M Aiello; Swan N Thung; Rebecca G Wells; Linda E Greenbaum; Ben Z Stanger Journal: Genes Dev Date: 2013-03-21 Impact factor: 11.361
Authors: Xiaobo Wang; Ze Zheng; Jorge Matias Caviglia; Kathleen E Corey; Tina M Herfel; Bishuang Cai; Ricard Masia; Raymond T Chung; Jay H Lefkowitch; Robert F Schwabe; Ira Tabas Journal: Cell Metab Date: 2016-10-27 Impact factor: 27.287
Authors: Masaki Mori; Robinson Triboulet; Morvarid Mohseni; Karin Schlegelmilch; Kriti Shrestha; Fernando D Camargo; Richard I Gregory Journal: Cell Date: 2014-02-27 Impact factor: 41.582
Authors: Jixin Dong; Georg Feldmann; Jianbin Huang; Shian Wu; Nailing Zhang; Sarah A Comerford; Mariana F Gayyed; Robert A Anders; Anirban Maitra; Duojia Pan Journal: Cell Date: 2007-09-21 Impact factor: 41.582
Authors: Karlin Raja Karlmark; Ralf Weiskirchen; Henning W Zimmermann; Nikolaus Gassler; Florent Ginhoux; Christian Weber; Miriam Merad; Tom Luedde; Christian Trautwein; Frank Tacke Journal: Hepatology Date: 2009-07 Impact factor: 17.425
Authors: Andrew G Cox; Katie L Hwang; Kristin K Brown; Kimberley Evason; Sebastian Beltz; Allison Tsomides; Keelin O'Connor; Giorgio G Galli; Dean Yimlamai; Sagar Chhangawala; Min Yuan; Evan C Lien; Julia Wucherpfennig; Sahar Nissim; Akihiro Minami; David E Cohen; Fernando D Camargo; John M Asara; Yariv Houvras; Didier Y R Stainier; Wolfram Goessling Journal: Nat Cell Biol Date: 2016-07-18 Impact factor: 28.824
Authors: Mladen Yovchev; Fadi L Jaber; Zhonglei Lu; Shachi Patel; Joseph Locker; Leslie E Rogler; John W Murray; Marius Sudol; Mariana D Dabeva; Liang Zhu; David A Shafritz Journal: Sci Rep Date: 2016-01-14 Impact factor: 4.379
Authors: Haibo Bai; Nailing Zhang; Yang Xu; Qian Chen; Mehtab Khan; James J Potter; Suresh K Nayar; Toby Cornish; Gianfranco Alpini; Steven Bronk; Duojia Pan; Robert A Anders Journal: Hepatology Date: 2012-08-08 Impact factor: 17.425
Authors: Xiaobo Wang; Bishuang Cai; Xiaoming Yang; Oluwatoni O Sonubi; Ze Zheng; Rajasekhar Ramakrishnan; Hongxue Shi; Luca Valenti; Utpal B Pajvani; Jaspreet Sandhu; Rodney E Infante; Arun Radhakrishnan; Douglas F Covey; Kun-Liang Guan; Jochen Buck; Lonny R Levin; Peter Tontonoz; Robert F Schwabe; Ira Tabas Journal: Cell Metab Date: 2020-04-06 Impact factor: 27.287